Role of Vascular Endothelial Growth Factor (VEGF) in Acute Lung Injury/Adult Respiratory Distress Syndrome (ARDS)
Respiratory Distress Syndrome, Adult
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Role of Vascular Endothelial Growth Factor (VEGF) in Acute Lung Injury/Adult Respiratory Distress Syndrome (ARDS)|
|Actual Study Start Date:||January 2006|
|Study Completion Date:||January 2017|
|Primary Completion Date:||January 2017 (Final data collection date for primary outcome measure)|
In previous lab experiments, we observed evidence of pulmonary edema following alveolar epithelial overexpression of VEGF, suggesting a potential role for VEGF in ARDS. In addition, we found that preventing VEGF from reaching its target receptor(s) by overexpressing a soluble form of a VEGF receptor protein prevents edema formation.
These observations heighten the plausibility of VEGF playing an important role in the development of increased pulmonary capillary permeability during acute lung injury. Understanding this role VEGF plays in ARDS consequently provides an ideal opportunity to discover new therapies for ARDS.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00319631
|United States, New York|
|Weill Medical College of Cornell University|
|New York City, New York, United States, 10021|
|Principal Investigator:||Robert J. Kaner, M.D.||Weill Medical College of Cornell University|